UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Exposure-Response Relationship of T-DM1: Insight Into Dose Optimization for Patients With HER2-Positive Metastatic Breast Cancer

Clinical pharmacology and therapeutics, 2014-05, Vol.95 (5), p.558-564

2014

Volltextzugriff (PDF)

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

The Lancet (British edition), 2014-07, Vol.384 (9938), p.164-172

2014

Volltextzugriff (PDF)

Real-world treatment patterns and outcomes among elderly metastatic triple negative breast cancer patients in the United States

Annals of oncology, 2017-09, Vol.28, p.v92-v92

2017

Volltextzugriff (PDF)

What are the treatment patterns and overall survival (OS) in patients with metastatic triple-negative breast cancer (mTNBC) in US clinical practice?

Annals of oncology, 2017-09, Vol.28, p.v87-v87

2017

Volltextzugriff (PDF)

Abstract P6-13-02: Increased mortality risk among elderly patients with early stage triple negative breast cancer who did not receive adjuvant or neoadjuvant therapy

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P6-P6-13-02

2018

Volltextzugriff (PDF)

Abstract OT3-05-01: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT3-05-01-OT3-05-01

2019

Volltextzugriff (PDF)

Second lung cancers in patients successfully treated for lung cancer: Lung cancer

Seminars in oncology, 1997-08, Vol.24 (4), p.492-499

1997

Volltextzugriff (PDF)

Developing drugs to decrease the toxicity of chemotherapy

Journal of clinical oncology, 2001-07, Vol.19 (14), p.3439-3441

2001

Volltextzugriff (PDF)

Trastuzumab cardiotoxicity: FDA review of four adjuvant breast cancer clinical trials leading to trastuzumab marketing approvals

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e11520-e11520

2009

Volltextzugriff (PDF)

Early targeted drug development: Pilot FDA review of PI3K inhibitor phase I studies using a knowledge management database

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3060-3060

2011

Volltextzugriff (PDF)

Relationship between OS and PFS in metastatic breast cancer (MBC): Review of FDA submission data

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.1035-1035

2011

Volltextzugriff (PDF)

Adjuvant breast cancer: FDA approval overview

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e11529-e11529

2009

Volltextzugriff (PDF)

Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing

Clinical cancer research, 1997-05, Vol.3 (5), p.741-747

1997

Volltextzugriff (PDF)

Targeted cancer therapies: FDA approval overview

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.2537-2537

2010

Volltextzugriff (PDF)

Abstract P5-17-01: A definition of a high-risk early-breast cancer population based on data from the collaborative trials in neoadjuvant breast cancer (CTNeoBC) meta-analysis

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P5-P5-17-01

2013

Volltextzugriff (PDF)

Review of the Efficacy of Individualized Chemotherapy Selected by In Vitro Drug Sensitivity Testing for Patients With Cancer

Journal of clinical oncology, 1999-05, Vol.17 (5), p.1625-1631

1999

Volltextzugriff (PDF)

Metastatic breast cancer (MBC): FDA approval overview

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.1013-1013

2008

Volltextzugriff (PDF)

Key drug development features in the design of early-phase oncology trials: An FDA perspective

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.2597-2597

2011

Volltextzugriff (PDF)

Abstract S1-11: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.S1-S1-11

2012

Volltextzugriff (PDF)

FDA evaluation of hepatotoxicity related to tyrosine kinase inhibitors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3106-3106

2011

Volltextzugriff (PDF)

Differences in prior estrogen exposure may explain the difference in magnitude of breast cancer risk reduction observed in raloxifene breast cancer prevention trials

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.1519-1519

2008

Volltextzugriff (PDF)

Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)

CANCER RESEARCH, 2012, Vol.72

2012

Volltextzugriff (PDF)

El Cuestionario de Capacidades y Dificultades (SDQ) como herramienta de cribado para el Trastorno por Déficit de Atención e Hiperactividad

Revista de psiquiatría infanto-juvenil, 2018-09, Vol.35 (3), p.255-263

2018

Volltextzugriff (PDF)

Trastorno por Déficit de Atención e Hiperactividad (TDAH), ¿se mantiene el diagnóstico de sospecha realizado en Atención Primaria en la Unidad de Salud Mental Infanto- Juvenil?

Revista de psiquiatría infanto-juvenil, 2017-03, Vol.34 (1), p.19-26

2017

Volltextzugriff (PDF)

179 In vitro drug sensitivity testing to select chemotherapy for patients with lung cancer

Lung cancer (Amsterdam, Netherlands), 1997-08, Vol.18, p.48-48

1997

Volltextzugriff (PDF)

1 – 25 von 215

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(189)
Mit Volltextzugriff
(187)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(125)
Life Sciences & Biomedicine
(84)
Humans
(39)
Physical Sciences
(38)
Female
(24)
Technology
(24)
Biological And Medical Sciences
(21)
Male
(20)
Exact Sciences And Technology
(19)
Adult
(17)
Agriculture
(17)
Middle Aged
(17)
Applied Sciences
(14)
Animals
(13)
Medical Sciences
(12)
Physics
(12)
Fundamental And Applied Biological Sciences. Psychology
(11)
Oncology
(10)
Aged
(9)
Agronomy
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Exposure-Response Relationship of T-DM1: Insight Into Dose Optimization for Patients With HER2-Positive Metastatic Breast Cancer

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Real-world treatment patterns and outcomes among elderly metastatic triple negative breast cancer patients in the United States

What are the treatment patterns and overall survival (OS) in patients with metastatic triple-negative breast cancer (mTNBC) in US clinical practice?

Abstract P6-13-02: Increased mortality risk among elderly patients with early stage triple negative breast cancer who did not receive adjuvant or neoadjuvant therapy

Abstract OT3-05-01: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze

Second lung cancers in patients successfully treated for lung cancer: Lung cancer

Developing drugs to decrease the toxicity of chemotherapy

Trastuzumab cardiotoxicity: FDA review of four adjuvant breast cancer clinical trials leading to trastuzumab marketing approvals

Early targeted drug development: Pilot FDA review of PI3K inhibitor phase I studies using a knowledge management database

Relationship between OS and PFS in metastatic breast cancer (MBC): Review of FDA submission data

Adjuvant breast cancer: FDA approval overview

Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing

Targeted cancer therapies: FDA approval overview

Abstract P5-17-01: A definition of a high-risk early-breast cancer population based on data from the collaborative trials in neoadjuvant breast cancer (CTNeoBC) meta-analysis

Review of the Efficacy of Individualized Chemotherapy Selected by In Vitro Drug Sensitivity Testing for Patients With Cancer

Metastatic breast cancer (MBC): FDA approval overview

Key drug development features in the design of early-phase oncology trials: An FDA perspective

Abstract S1-11: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)

FDA evaluation of hepatotoxicity related to tyrosine kinase inhibitors

Differences in prior estrogen exposure may explain the difference in magnitude of breast cancer risk reduction observed in raloxifene breast cancer prevention trials

Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)

El Cuestionario de Capacidades y Dificultades (SDQ) como herramienta de cribado para el Trastorno por Déficit de Atención e Hiperactividad

Trastorno por Déficit de Atención e Hiperactividad (TDAH), ¿se mantiene el diagnóstico de sospecha realizado en Atención Primaria en la Unidad de Salud Mental Infanto- Juvenil?

179 In vitro drug sensitivity testing to select chemotherapy for patients with lung cancer

Suchergebnisse filtern